News | June 09, 2023
Croda breaks ground on lipid manufacturing facility in Pennsylvania
Construction will begin this year with the new capacity anticipated by 2025
Construction will begin this year with the new capacity anticipated by 2025
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
The partnership will capitalize on the combined capabilities of the two organizations
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Fully equipped labs with 75-member team set-up and made operational in <100 days
From cancer research to diagnostic solutions
Subscribe To Our Newsletter & Stay Updated
